FinscoFinsco

ACADIA Pharmaceuticals (US.ACAD)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ACAD · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion84.7%↑
ROE0.3%↓
Cash Conversion934.3%↑
D/E Ratio0.04↑
Gross Margin90.8%→
US.ACAD (ACADIA Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion    84.7%    ↑
ROE                0.3%    ↓
Cash Conversion  934.3%    ↑
D/E Ratio          0.04    ↑
Gross Margin      90.8%    →
Key Metrics
US.ACAD (ACADIA Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 84.7% ↑
ROE 0.3% ↓
Cash Conversion 934.3% ↑
D/E Ratio 0.04 ↑
Gross Margin 90.8% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies